BR122018073034B8 - - Google Patents

Info

Publication number
BR122018073034B8
BR122018073034B8 BR122018073034A BR122018073034A BR122018073034B8 BR 122018073034 B8 BR122018073034 B8 BR 122018073034B8 BR 122018073034 A BR122018073034 A BR 122018073034A BR 122018073034 A BR122018073034 A BR 122018073034A BR 122018073034 B8 BR122018073034 B8 BR 122018073034B8
Authority
BR
Brazil
Application number
BR122018073034A
Other languages
Portuguese (pt)
Other versions
BR122018073034B1 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/857,484 external-priority patent/US7622564B2/en
Application filed filed Critical
Priority claimed from PCT/US2005/017412 external-priority patent/WO2005118864A2/en
Publication of BR122018073034B1 publication Critical patent/BR122018073034B1/pt
Publication of BR122018073034B8 publication Critical patent/BR122018073034B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
BR122018073034-0A 2004-05-28 2005-05-17 Anticorpos e moléculas relacionadas que se ligam à proteínas de psca BR122018073034B1 (pt)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US10/857,484 US7622564B2 (en) 2003-05-30 2004-05-28 Prostate stem cell antigen (PSCA) variants and subsequences thereof
PCT/US2004/017231 WO2005014780A2 (en) 2003-05-30 2004-05-28 Prostate stem cell antigen (psca) variants and subsequences thereof
US61638104P 2004-10-05 2004-10-05
US60/616,381 2004-10-05
US61788104P 2004-10-12 2004-10-12
US60/617,881 2004-10-12
US62131004P 2004-10-21 2004-10-21
US60/621,310 2004-10-21
US63307704P 2004-12-02 2004-12-02
US60/633,077 2004-12-02
US67200005P 2005-04-14 2005-04-14
US60/672,000 2005-04-14
PCT/US2005/017412 WO2005118864A2 (en) 2004-05-28 2005-05-17 Antibodies and related molecules that bind to psca proteins

Publications (2)

Publication Number Publication Date
BR122018073034B1 BR122018073034B1 (pt) 2021-10-13
BR122018073034B8 true BR122018073034B8 (cg-RX-API-DMAC10.html) 2022-10-11

Family

ID=44210117

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0511624-4A BRPI0511624B1 (pt) 2004-05-28 2005-05-17 Anticorpo monoclonal que se liga à proteína psca, uso do mesmo, hibridoma, vetor, composição farmacêutica, bem como ensaio e método para detecção da presença de uma proteína psca em uma amostra biológica
BRPI0520902-1A BRPI0520902B1 (pt) 2004-05-28 2005-05-17 Anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo que se liga a proteínas psca para diagnóstico de câncer, método para produção dos mesmos, hibridoma, polinucleotídeo, vetor, composição, ensaio para detectar a presença de uma proteína psca e método de detecção de uma proteína psca
BR122018073034-0A BR122018073034B1 (pt) 2004-05-28 2005-05-17 Anticorpos e moléculas relacionadas que se ligam à proteínas de psca

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BRPI0511624-4A BRPI0511624B1 (pt) 2004-05-28 2005-05-17 Anticorpo monoclonal que se liga à proteína psca, uso do mesmo, hibridoma, vetor, composição farmacêutica, bem como ensaio e método para detecção da presença de uma proteína psca em uma amostra biológica
BRPI0520902-1A BRPI0520902B1 (pt) 2004-05-28 2005-05-17 Anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo que se liga a proteínas psca para diagnóstico de câncer, método para produção dos mesmos, hibridoma, polinucleotídeo, vetor, composição, ensaio para detectar a presença de uma proteína psca e método de detecção de uma proteína psca

Country Status (6)

Country Link
KR (2) KR101282396B1 (cg-RX-API-DMAC10.html)
CN (1) CN102344493B (cg-RX-API-DMAC10.html)
BR (3) BRPI0511624B1 (cg-RX-API-DMAC10.html)
IL (1) IL214210A (cg-RX-API-DMAC10.html)
NO (1) NO341404B1 (cg-RX-API-DMAC10.html)
SI (1) SI1753871T1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107102142A (zh) 2007-03-27 2017-08-29 伊缪诺维亚公司 检测腺癌的蛋白标志/标记
MX364265B (es) * 2012-08-23 2019-04-17 Agensys Inc Conjugados de anticuerpo farmaco (adc) que enlazan a las proteinas 158p1d7.
HK1213481A1 (zh) 2012-12-13 2016-07-08 The Trustees Of The University Of Pennsylvania Dna抗体构建体及其使用方法
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
US10087240B2 (en) 2013-12-13 2018-10-02 Inovio Pharmaceuticals, Inc. DNA antibody constructs and method of using same
CA2969214A1 (en) 2014-12-01 2016-06-09 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN119930826A (zh) * 2023-11-02 2025-05-06 重庆精准生物产业技术研究院有限公司 针对psca的全人源单链抗体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258939B1 (en) * 1997-03-10 2001-07-10 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
EP0981541B1 (en) * 1997-03-10 2004-06-02 The Regents Of The University Of California Psca: prostate stem cell antigen
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
BR0015224A (pt) * 1999-10-29 2002-07-09 Genentech Inc Anticorpo anti-antìgeno de célula estaminal prostática (psca) isolado, anticorpo monoclonal anti-psca, ácido nucleico isolado, vetor de expressão, célula, célula hospedeira, método de produção de anticorpo, composição método in vitro para matar uma célula cancerosa que expresse psca, uso de uma anticorpo monoclonal anti-psca e artigo industrializado

Also Published As

Publication number Publication date
BRPI0511624B1 (pt) 2022-02-08
KR101282396B1 (ko) 2013-07-04
BRPI0520902A2 (pt) 2011-10-25
NO341404B1 (no) 2017-10-30
SI1753871T1 (sl) 2016-01-29
BRPI0520902B1 (pt) 2021-11-30
NO20110647L (no) 2006-12-19
IL214210A (en) 2013-01-31
KR20070047251A (ko) 2007-05-04
CN102344493B (zh) 2014-09-03
KR20110056564A (ko) 2011-05-30
BRPI0511624A (pt) 2008-01-02
IL214210A0 (en) 2011-08-31
KR101215611B1 (ko) 2012-12-28
CN102344493A (zh) 2012-02-08
BR122018073034B1 (pt) 2021-10-13

Similar Documents

Publication Publication Date Title
BE2024C508I2 (cg-RX-API-DMAC10.html)
BE2023C542I2 (cg-RX-API-DMAC10.html)
BE2022C549I2 (cg-RX-API-DMAC10.html)
BE2021C001I2 (cg-RX-API-DMAC10.html)
BE2020C513I2 (cg-RX-API-DMAC10.html)
BE2020C517I2 (cg-RX-API-DMAC10.html)
BE2019C540I2 (cg-RX-API-DMAC10.html)
BE2019C523I2 (cg-RX-API-DMAC10.html)
BE2019C548I2 (cg-RX-API-DMAC10.html)
BE2019C506I2 (cg-RX-API-DMAC10.html)
BE2018C045I2 (cg-RX-API-DMAC10.html)
BE2020C525I2 (cg-RX-API-DMAC10.html)
BE2017C063I2 (cg-RX-API-DMAC10.html)
BE2017C027I2 (cg-RX-API-DMAC10.html)
BE2017C023I2 (cg-RX-API-DMAC10.html)
BE2017C002I2 (cg-RX-API-DMAC10.html)
BE2016C067I2 (cg-RX-API-DMAC10.html)
BE2016C014I2 (cg-RX-API-DMAC10.html)
BE2015C041I2 (cg-RX-API-DMAC10.html)
BE2015C038I2 (cg-RX-API-DMAC10.html)
BE2015C014I2 (cg-RX-API-DMAC10.html)
BE2014C071I2 (cg-RX-API-DMAC10.html)
BE2015C015I2 (cg-RX-API-DMAC10.html)
BE2014C064I2 (cg-RX-API-DMAC10.html)
BE2014C063I2 (cg-RX-API-DMAC10.html)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/05/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2649 DE 13/10/2021, QUANTO AO ITEM (54) TITULO.